Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kendra Sweet

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Blood Advances|August 19, 2025
Asciminib in late-line CML treatmentKendra Sweet, Javier Pinilla-Ibarz
Frontiers in Oncology|July 16, 2024
Exploring treatment decision-making in chronic myeloid leukemia in chronic phaseDavid Andorsky, Vamsi Kota, Kendra Sweet
Patient Preference and Adherence|July 22, 2014
Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerationsKendra Sweet, Javier Pinilla-Ibarz, Ling Zhang
Journal of Hematology & Oncology|July 23, 2013
Biomarkers for determining the prognosis in chronic myelogenous leukemiaKendra Sweet, Ling Zhang, Javier Pinilla-Ibarz
Anticancer Research|December 6, 2015
Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid LeukemiaJavier Pinilla-Ibarz, Kendra Sweet, Josephine Emole, et al.
Expert Review of Hematology|March 12, 2019
Can increased immunogenicity in chronic myeloid leukemia improve outcomes?Onyee Chan, Chetasi Talati, Kendra Sweet, et al.
Leukemia & Lymphoma|March 20, 2023
The impact of mild-to-moderate chronic kidney disease on hospitalization outcomes in patients with acute myeloid leukemiaMohammad Ammad Ud Din, Hassan Saeed, Moazzam Shahzad, et al.
Cureus|May 4, 2022
Gilteritinib Combined with Azacitidine as Salvage Therapy for B/Myeloid Mixed Phenotype Acute LeukemiaNathan P Horvat, Constantine N Logothetis, Ling Zhang, et al.
Annals of Hematology|July 18, 2024
Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemiaJeffrey H Lipton, Tim H Brümmendorf, Kendra Sweet, et al.
Blood Advances|February 12, 2020
Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemiaOnyee Chan, Chetasi Talati, Leidy Isenalumhe, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Blood Advances|August 19, 2025
Asciminib in late-line CML treatmentKendra Sweet, Javier Pinilla-Ibarz
Frontiers in Oncology|July 16, 2024
Exploring treatment decision-making in chronic myeloid leukemia in chronic phaseDavid Andorsky, Vamsi Kota, Kendra Sweet
Patient Preference and Adherence|July 22, 2014
Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerationsKendra Sweet, Javier Pinilla-Ibarz, Ling Zhang
Journal of Hematology & Oncology|July 23, 2013
Biomarkers for determining the prognosis in chronic myelogenous leukemiaKendra Sweet, Ling Zhang, Javier Pinilla-Ibarz
Anticancer Research|December 6, 2015
Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid LeukemiaJavier Pinilla-Ibarz, Kendra Sweet, Josephine Emole, et al.
Expert Review of Hematology|March 12, 2019
Can increased immunogenicity in chronic myeloid leukemia improve outcomes?Onyee Chan, Chetasi Talati, Kendra Sweet, et al.
Leukemia & Lymphoma|March 20, 2023
The impact of mild-to-moderate chronic kidney disease on hospitalization outcomes in patients with acute myeloid leukemiaMohammad Ammad Ud Din, Hassan Saeed, Moazzam Shahzad, et al.
Cureus|May 4, 2022
Gilteritinib Combined with Azacitidine as Salvage Therapy for B/Myeloid Mixed Phenotype Acute LeukemiaNathan P Horvat, Constantine N Logothetis, Ling Zhang, et al.
Annals of Hematology|July 18, 2024
Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemiaJeffrey H Lipton, Tim H Brümmendorf, Kendra Sweet, et al.
Blood Advances|February 12, 2020
Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemiaOnyee Chan, Chetasi Talati, Leidy Isenalumhe, et al.
Pageof 9